A PHASE 2 STUDY OF THE ANTI-TUMOUR ACTIVITY AND SAFETY OF PROLARIX™ IN HEPATOCELLULAR CARCINOMA (HCC)

Update Il y a 4 ans
Reference: EUCTR2008-000912-34

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the overall response rate [ie, proportion of subjects with complete response (CR) and partial response (PR)] to treatment with Prolarix at the MTD determined in a previous Phase 1 study (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide).


Inclusion criteria

  • Hepatocellular carcinoma (HCC)